Next Article in Journal
Multistable Perception in Older Adults: Constructing a Whole from Fragments
Previous Article in Journal
Exercise Strengthens Central Nervous System Modulation of Pain in Fibromyalgia
Open AccessArticle

Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood

Institute of Chronic Illnesses, Inc., Silver Spring, MD 20905, USA
CoMeD, Inc., Silver Spring, MD 20905, USA
Council for Nutritional and Environmental Medicine, Mo i Rana, Norway
Department of Biology, Simpson University, Redding, CA 96003, USA
Focus for Health, Watchung, NJ 07069, USA
Author to whom correspondence should be addressed.
Academic Editor: Balapal S. Basavarajappa
Brain Sci. 2016, 6(1), 9;
Received: 27 December 2015 / Revised: 6 March 2016 / Accepted: 8 March 2016 / Published: 15 March 2016
(1) Background: Hyperkinetic syndrome of childhood (HKSoC) is an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) category in which the majority of the children are also diagnosed under the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR), where the umbrella term is “Attention-Deficit and Disruptive Behavior Disorders”. The diagnostic criteria for HKSoC are developmentally inappropriate inattention, hyperactivity, and impulsivity. Some studies have implicated mercury (Hg) exposure as a risk factor. (2) Methods: This hypothesis testing study; using the Vaccine Safety Datalink; assessed the toxicological effects of bolus exposure to organic-Hg from Thimerosal-containing vaccines (TCVs) by examining the relationship between Thimerosal-preserved hepatitis B vaccines (TM-HepB) given at varying levels and at specific intervals in the first six months after birth and the risk of a child being diagnosed with HKSoC. (3) Results: Children diagnosed with HKSoC were significantly more likely to be exposed to increased organic-Hg from TM-HepB doses given within the first month (odds ratio = 1.45; 95% confidence interval (CI) = 1.30–1.62); within the first two months (odds ratio = 1.43; 95% CI = 1.28–1.59); and within the first six months (odds ratio = 4.51; 95% CI = 3.04–6.71) than controls. (4) Conclusion: The results indicate that increasing organic-Hg exposure from TCVs heightens the risk of a HKSoC diagnosis. View Full-Text
Keywords: ADHD; Thimerosal; neurodevelopmental disorder; Hyperkinetic syndrome of childhood ADHD; Thimerosal; neurodevelopmental disorder; Hyperkinetic syndrome of childhood
MDPI and ACS Style

Geier, D.A.; Kern, J.K.; Hooker, B.S.; Sykes, L.K.; Geier, M.R. Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood. Brain Sci. 2016, 6, 9.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop